Rituximab for non-responsive idiopathic membranous nephropathy in a Chinese cohort | Zendy

Xin Wang | Zendy; Zhao Cui | Zendy; Yi-miao Zhang | Zendy; Zhen Qu | Zendy; Fang Wang | Zendy; Liqiang Meng | Zendy; Pengcheng Xu | Zendy; Gang Liu | Zendy; Fu-de Zhou | Zendy; MingHui Zhao | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rituximab for non-responsive idiopathic membranous nephropathy in a Chinese cohort

Author(s) -

Xin Wang,

Zhao Cui,

Yi-miao Zhang,

Zhen Qu,

Fang Wang,

Liqiang Meng,

Pengcheng Xu,

Gang Liu,

Fu-de Zhou,

MingHui Zhao

Publication year - 2017

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfx295

Subject(s) - medicine , rituximab , interquartile range , membranous nephropathy , gastroenterology , renal function , nephrotic syndrome , kidney disease , immunosuppression , antibody , urology , immunology , surgery , kidney , glomerulonephritis

Rituximab had been shown to be effective in inducing remission of nephrotic syndrome in patients with idiopathic membranous nephropathy (iMN). This study applied rituximab therapy for 36 non-responsive iMN patients to investigate its effects and safety.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research